论文部分内容阅读
目的探讨早期鼻咽癌(T1-2N0-1M0)患者放疗前、后血清TGF-β1水平的变化,分析其与临床分期和近期疗效的关系。方法 2010年2月10日至2011年7月3日共入组早期鼻咽癌初治患者57例,根据入组患者放疗前的血清TGF-β1含量,将入组患者分为两组:A组29例:血清TGF-β1值低于或等于标准值的患者;B组28例:血清TGF-β1值高于标准值的患者。观察患者放疗前、放疗至40 Gy、放疗后的血清TGF-β1含量。应用酶联免疫吸附测定(ELISA)法检测血清TGF-β1含量。选取32例健康志愿者的平均血清TGF-β1水平(50.2±3.2 ng/ml)作为本试验患者的标准值。结果 57例患者放疗前血清TGF-β1水平为(46.9±1.8)ng/ml,与健康志愿者比较差异无统计学意义(P>0.05)。而57例患者放疗中、放疗后的血清TGF-β1水平为分别为(23.2±1.0)ng/ml和(19.4±0.7)ng/ml,与健康志愿者及放疗前比较,差异有统计学意义(P<0.05)。A、B两组放疗前血清TGF-β1水平比较差异有统计学意义[(35.4±1.4)ng/ml vs(58.8±1.0)ng/ml,P<0.05];而两组放疗中、放疗后的血清TGF-β1水平比较差异无统计学意义(P>0.05)。两组患者的鼻咽病灶及颈部淋巴结的缓解率比较差异无统计学意义(P>0.05)。T1和T2分期患者放疗前、放疗中、放疗后的血清TGF-β1水平比较差异无统计学意义P>0.05);N0、N1a和N1b分期患者放疗前、放疗中、放疗后的的血清TGF-β1水平比较差异无统计学意义()P>0.05)。结论放疗能明显降低早期鼻咽癌患者的血清TGF-β1水平。患者放疗前、放疗中、放疗后的血清TGF-β1水平与T、N分期无关,也不能有效监测肿瘤客观反应率。
Objective To investigate the changes of serum TGF-β1 levels in patients with early nasopharyngeal carcinoma (T1-2N0-1M0) before and after radiotherapy, and to analyze the relationship between serum TGF-β1 levels and clinical staging and short-term efficacy. Methods A total of 57 patients with early stage nasopharyngeal carcinoma were enrolled from February 10, 2010 to July 3, 2011. According to the serum TGF-β1 levels before radiotherapy in the enrolled patients, the enrolled patients were divided into two groups: In 29 patients: patients with serum TGF-β1 values below or equal to the standard values; 28 patients in group B: patients with serum TGF-β1 values above the standard values. Observe the content of serum TGF-β1 before and after radiotherapy to 40 Gy and radiotherapy. The serum TGF-β1 level was detected by enzyme-linked immunosorbent assay (ELISA). The mean serum TGF-β1 level (50.2±3.2 ng/ml) in 32 healthy volunteers was selected as the standard value in this trial. Results Serum levels of TGF-β1 were (46.9±1.8) ng/ml in 57 patients before radiotherapy. There was no significant difference between healthy volunteers and normal volunteers (P>0.05). The serum TGF-β1 levels in 57 patients after radiotherapy and radiotherapy were (23.2±1.0) ng/ml and (19.4±0.7) ng/ml, respectively, and the difference was statistically significant before and after radiotherapy in healthy volunteers. (P<0.05). There was significant difference in serum TGF-β1 levels between group A and B before radiotherapy (35.4±1.4) ng/ml vs (58.8±1.0) ng/ml, P<0.05]; There was no significant difference in serum TGF-β1 levels after radiotherapy (P>0.05). There was no significant difference in the remission rate of nasopharyngeal lesions and cervical lymph nodes between the two groups (P>0.05). There was no significant difference in serum TGF-β1 levels before, during, and after radiotherapy in patients with T1 and T2 staging (P>0.05); serum TGF-β levels before, during, and after radiotherapy in patients with N0, N1a, and N1b staging There was no significant difference in the level of β1 (P>0.05). Conclusion Radiotherapy can significantly reduce serum TGF-β1 levels in patients with early nasopharyngeal carcinoma. Serum TGF-β1 levels before radiotherapy, radiotherapy, and radiotherapy were not associated with T and N staging, nor could they effectively monitor the objective response rate of the tumor.